News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
16 Sep 2022
Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.
16 Sep 2022

Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022
Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.
16 Sep 2022

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
byRoshini Claire Anthony
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
15 Sep 2022





